Dynavax to Participate at the 8th Annual Evercore Healthcare Conference

Core Viewpoint - Dynavax Technologies Corporation is actively participating in the 8th Annual Evercore Healthcare Conference, indicating its ongoing engagement with investors and the healthcare community [1]. Company Overview - Dynavax is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative vaccines to combat infectious diseases [3]. - The company has two commercial products: HEPLISAV-B, a hepatitis B vaccine approved in the U.S., EU, and UK for adults aged 18 and older, and the CpG 1018 adjuvant, utilized in HEPLISAV-B and various adjuvanted COVID-19 vaccines [3]. Investor Engagement - The upcoming fireside chat at the Evercore Healthcare Conference is scheduled for December 2nd at 2:10 p.m. ET, which will be accessible via the company's website [1][2].